Arcus Biosciences Net Income 2017-2022 | RCUS

Arcus Biosciences net income from 2017 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Arcus Biosciences Annual Net Income
(Millions of US $)
2021 $53
2020 $-123
2019 $-85
2018 $-50
2017 $-53
2016 $-18
Arcus Biosciences Quarterly Net Income
(Millions of US $)
2022-09-30 $-65
2022-06-30 $-67
2022-03-31 $-68
2021-12-31 $279
2021-09-30 $-78
2021-06-30 $-76
2021-03-31 $-73
2020-12-31 $-52
2020-09-30 $2
2020-06-30 $-45
2020-03-31 $-28
2019-12-31 $-17
2019-09-30 $-22
2019-06-30 $-28
2019-03-31 $-18
2018-12-31 $-12
2018-09-30 $-11
2018-06-30 $-14
2018-03-31 $-13
2017-12-31 $-13
2017-09-30 $-23
2017-06-30 $-10
2017-03-31 $-7
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.934B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.552B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00